Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 17/09/2018 | Race signs agreement with NSF Health Sciences to file IND | Download |
| 13/09/2018 | Investor Presentation-Broker Meets Biotech Conference | Download |
| 30/08/2018 | Appendix 3Y-Bill Garner | Download |
| 28/08/2018 | Appendix 3Y - Peter Molloy | Download |
| 23/08/2018 | Management and services changes at Race Oncology | Download |
| 21/08/2018 | Appendix 4G | Download |
| 21/08/2018 | Appendix 4E & Financial Statements | Download |
| 03/08/2018 | Investor Presentation | Download |
| 27/07/2018 | June 2018 Quarterly Report | Download |
| 18/07/2018 | FDA Grants Bisantrene Rare Paediatric Disease Designation | Download |
ASX: RAC
Price
Latest News
Race signs agreement with NSF Health Sciences to file IND
Race Oncology is pleased to announce it has executed an agreement with Washington D.C –
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Race Oncology is pleased to announce that it has received a letter from the FDA advising that
Chart: Long-term survival case report of patients treated with Bisantrene Combination Therapy
The chart below details the long-term survival case report of two paediatric relapsed or
Don't miss important updates
Get the latest news & announcement and stay up-to-date.